CSIMarket Company Name, Ticker, Competitors, else..
 
Inovio Pharmaceuticals Inc   (INO)
Other Ticker:  
 
 
Price: $6.8100 $0.18 2.715%
Day's High: $6.8899 Week Perf: 6.24 %
Day's Low: $ 6.68 30 Day Perf: -12.92 %
Volume (M): 213 52 Wk High: $ 14.75
Volume (M$): $ 1,448 52 Wk Avg: $7.99
Open: $6.69 52 Wk Low: $3.89



 Market Capitalization (Millions $) 185
 Shares Outstanding (Millions) 27
 Employees -
 Revenues (TTM) (Millions $) 7
 Net Income (TTM) (Millions $) -122
 Cash Flow (TTM) (Millions $) -18
 Capital Exp. (TTM) (Millions $) 0

Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a biotechnology company that focuses on the development and commercialization of DNA immunotherapies to treat and prevent infectious diseases, cancer, and other medical conditions. The company's innovative platform, called SynCon, allows for the rapid design and production of DNA-based vaccines and immune therapies. Inovio's technology aims to stimulate the body's immune system to target specific diseases, potentially providing safer and more effective treatment options.

Inovio has a diverse pipeline of product candidates in various stages of development, including treatments for HPV-related cancers, hepatitis B, HIV, and Zika virus, among others. The company has also recently gained attention for its efforts in developing a COVID-19 vaccine candidate, which has shown promising results in preclinical studies.

In addition to its research and development activities, Inovio has collaborations and partnerships with various organizations, including academic institutions, biopharmaceutical companies, and government agencies, to further advance its technology and expand its product portfolio.

Overall, Inovio Pharmaceuticals Inc is committed to leveraging its innovative DNA-based platform to address unmet medical needs and improve patient outcomes in the field of immunotherapy.


   Company Address: 660 W. Germantown Pike Plymouth Meeting 19462 PA
   Company Phone Number: 440-4200   Stock Exchange / Ticker: NASDAQ INO


   

Stock Performances by Major Competitors

5 Days Decrease / Increase
     
• View Complete Report
   



Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc. Confronts Significant Challenges Amid Promising Second Quarter of 2024 Financial Performance


A Bearish Outlook on Inovio Pharmaceuticals Inc: A Closer Examination
Inovio Pharmaceuticals Inc finds itself at a crossroads as it navigates through the second quarter of 2024, clearly trailing behind the norms set by the broader Medical Equipment & Supplies sector. With a revenue decline of 41.186% year-over-year, dropping from $2.39 million last year to a mere $1.41 million this year, Inovio is signaling troubling trends that cannot be ignored. Although the company has decreased its loss per share from $-1.56 to $-1.19 compared to the previous year, this improvement only highlights the underlying challenges that remain resolutely unaddressed.


A Shriveling Revenue Landscape
The drastic revenue contraction of over 41% is an immediate red flag for investors and stakeholders. While the company attempts to paint a rosy picture with decreased losses, it is essential to focus on the scale and sustainability of its revenues. While some might argue that the year-over-year loss reduction could be a positive indicator for Inovio?s financial health, the stark reality is that the company is generating significantly less revenue than it did a year prior.
Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc. Reports Disappointing First Quarter Results with Net Loss per Share of $-1.31

Investors in Inovio Pharmaceuticals Inc. were left disappointed after the company disclosed its first-quarter results for 2024, which showed a significant decrease in revenue and a higher net loss per share compared to the same period in 2023. The company reported a revenue decrease of -35.391% to $1.50 million and a net loss per share of $-1.31, in comparison to $-1.92 in the first quarter of 2023.
This news comes in stark contrast to the rest of the Medical Equipment & Supplies industry, which saw a revenue gain in the first quarter of 2024. Inovio Pharmaceuticals Inc. reported a net loss of $-30.470 million in the first quarter of 2024, an improvement from the $-40.649 million loss in the same period a year ago.
Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc Reports Soft Business Performance in Fiscal Fourth Quarter of 2023

As a financial analyst and writer for the , I have been closely monitoring the recent financial results of Inovio Pharmaceuticals Inc, a prominent player in the Medical Equipment & Supplies sector. The company's performance in the October to December 31, 2023 time-frame has displayed both positive and concerning signs.
One aspect that stands out is Inovio Pharmaceuticals' ability to trim its losses significantly in comparison to the previous year. Despite facing vanishing revenues, the company achieved a substantial decrease in its shortfall per share. In the reporting season a year prior, the company experienced an EPS of $-2.25, while in the current period, it has managed to reduce the shortfall to $-1.03 per share.
Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc Faces Astonishing Deficit of $-0.13 per Share in Explosive Fiscal Year-End Report for 2023

Inovio Pharmaceuticals Inc - A Bullish Outlook Despite Recent Setbacks
In the midst of challenging times for the Medical Equipment & Supplies industry, Inovio Pharmaceuticals Inc has managed to showcase its resilience and potential for growth. The company's recent financial report, covering the fiscal time-frame ending September 30, 2023, reveals some notable improvements compared to the same period a year ago.
While it is true that the company incurred a loss of $-0.13 per share, this figure demonstrates an improvement from the previous year's loss of $-0.15 per share. Moreover, it is worth noting that the loss remained consistent with the prior quarter. This stability in performance suggests that the company has managed to maintain a steady footing despite the challenges faced by the industry.
Inovio Pharmaceuticals Inc

Inovio Pharmaceuticals Inc Shows Remarkable Financial Improvement in Q2 2023 Despite Stock Decline


Date: INSERT DATE
Inovio Pharmaceuticals Inc (NASDAQ: INO) has reported positive developments during the second quarter of the 2023 earnings season, as the company managed to significantly reduce losses per share compared to the previous year. Additionally, Inovio's income per share showed improvement when compared to the prior reporting season. However, these achievements were overshadowed by the stock's recent performance, which has seen a decline of -70.99% year-to-date.
During the second quarter of 2023, Inovio Pharmaceuticals reported a loss per share of $-0.13, a substantial decrease from the $-0.46 recorded a year ago. The company's income per share also showed improvement, rising from $-0.16 during the prior reporting season. These positive shifts can be attributed to a revenue jump of 45.805%, reaching $2.39 million from $1.64 million in the same reporting period the previous year. Additionally, sequential revenue experienced a modest increase of 3.104% from $2.32 million.
In comparison to its industry counterparts, Inovio Pharmaceuticals appears to have outperformed on the top-line, with the Medical Equipment & Supplies industry reporting only a 3.90% revenue rise during the same period. Despite these notable achievements, it is important to scrutinize the company's recent stock performance for a more holistic understanding of its investment potential.






Inovio Pharmaceuticals Inc's Segments





Help

About us

Advertise
CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com